Php38 - Enzyme Replacement Therapies Within the German Hta (Amnog) Process

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.934
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Php139 - G-Ba Conditional Approvals in the Amnog Procedure: Impact on Hta Outcomes and Price

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Utilization and Evaluation of Delphi Panels in German Amnog Assessments

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Access to New Therapies in Romania Through the Scorecard HTA System

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

The Demand for Nicotine Replacement Therapies

Nicotine and Tobacco Research
EnvironmentalPublic HealthOccupational Health
2003English

The Demand for Nicotine Replacement Therapies

2001English

Non-Quantifiable Benefit Within the German Amnog System: Factors Contributing to Time Limits Set for Benefit Resolutions and Potential Implications on Price Discounts

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

HTA – Algorithm or Process? Comment on "Expanded HTA: Enhancing Fairness and Legitimacy"

International Journal of Health Policy and Management
Health Information ManagementManagementMonitoringHealth PolicyLeadershipHealthPolicyLaw
2016English

Pnd99 - Cystic Fibrosis Therapies - Key Drivers Behind Differing Hta Decisions

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Off Label Therapies for Testosterone Replacement

Translational Andrology and Urology
Reproductive MedicineUrology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy